{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:26:20Z","timestamp":1783635980466,"version":"3.55.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hepatoid adenocarcinoma of the stomach (HAS) is a rare subtype of gastric cancer (GC) characterized by alpha-fetoprotein (AFP) production and invasive liver and lymph node metastases, typically associated with a poor prognosis. Although immuno-chemotherapy has made significant achievements in the conversion therapy of advanced GC in recent years, the management of HER2-negative, proficient mismatch repair (pMMR), and a programmed cell death ligand-1 (PD-L1) combined positive score (CPS)&amp;lt;5 cases, particularly in the context of synchronous multiple liver metastases and lymph node involvement, poses significant challenges. This is attributable not only to its rapid progression but also to its poor prognosis. We retrospectively report a case of HAS with concurrent multiple liver and lymph node metastases. Following six cycles of immuno-chemotherapy, R0 resection was achieved, and postoperative pathological examination confirmed a pathological complete response (pCR). No recurrence or metastasis was observed at the 32-month postoperative follow-up (last follow-up: April 26, 2025). To our knowledge, no previous reports have documented pCR in HER2-negative, pMMR, and PD-L1 CPS&amp;lt;5 patients with advanced HAS following conversion therapy with combined immuno-chemotherapy. This report aims to provide further clinical reference for the treatment of advanced HAS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>A 51-year-old male patient was diagnosed with HAS accompanied by multiple liver and lymph node metastases. Following six cycles of immunotherapy (sintilimab) combined with chemotherapy (Nab-paclitaxel, oxaliplatin, and S-1), the primary tumor exhibited significant reduction. Multiple liver metastases showed partial shrinkage or disappearance (the target lesion diameter must be less than 10 mm), and retroperitoneal lymph nodes were no longer detectable. After thorough evaluation, R0 resection was deemed achievable. Therefore, radical distal gastrectomy with D2 lymphadenectomy and liver metastasectomy were performed. Postoperative pathology confirmed pCR. The patient has remained progression-free survival (PFS) for 32 months and overall survival (OS) for 38 months, with no evidence of recurrence or metastasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>HAS is a highly invasive malignant tumor of the stomach. The dynamic changes in AFP serve as a reliable indicator for detecting HAS, evaluating treatment efficacy, and predicting recurrence. In advanced HER-2-negative, PD-L1 CPS&amp;lt;5, pMMR-type HAS, employing a conversion therapy regimen combining sintilimab with Nab-paclitaxel, oxaliplatin, and S-1 may reduce tumor staging, enhance conversion therapy success rates, and prolong survival.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1648766","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T04:13:19Z","timestamp":1759378399000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pathologic complete response of advanced hepatoid adenocarcinoma of the stomach following immuno-chemotherapy and conversion surgery: a rare case report and review of the literature"],"prefix":"10.3389","volume":"15","author":[{"given":"Yaoqi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxu","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/s1470-2045(20)30460-5","article-title":"Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study","volume":"21","author":"Jin","year":"2020","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1494007","article-title":"Hyperprogression disease induced by Sintilimab combined with Oxaliplatin and S-1 after surgery: a case report and literature review","volume":"15","author":"Li","year":"2025","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.71449","article-title":"Integrative analysis reveals a clinicogenomic landscape associated with liver metastasis and poor prognosis in hepatoid adenocarcinoma of the stomach","volume":"18","author":"Jiang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/jso.23073","article-title":"An analysis of clinicopathological features and prognosis by comparing hepatoid adenocarcinoma of the stomach with AFP-producing gastric cancer","volume":"106","author":"Liu","year":"2012","journal-title":"J Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"Jama"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-015-0575-z","article-title":"Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification","volume":"19","author":"Yoshida","year":"2016","journal-title":"Gastric Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ags3.12515","article-title":"International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1)","volume":"6","author":"Yoshida","year":"2022","journal-title":"Ann Gastroenterol Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000738","article-title":"Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer","volume":"109","author":"Liang","year":"2023","journal-title":"Int J Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","article-title":"Recent developments in immunotherapy for gastrointestinal tract cancers","volume":"17","author":"Chong","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.4023","article-title":"Hepatoid adenocarcinoma of the stomach: A case report of a rare type of gastric cancer","volume":"11","author":"Shen","year":"2016","journal-title":"Oncol Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4372","article-title":"\u03b1-fetoprotein-producing gastric carcinoma: A case report of a rare subtype and literature review","volume":"11","author":"Sun","year":"2016","journal-title":"Oncol Lett"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00164","article-title":"Hepatoid adenocarcinoma of the stomach: A challenging diagnostic and therapeutic disease through a case report and review of the literature","volume":"4","author":"Fakhruddin","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-21-287","article-title":"Hepatoid esophagogastric adenocarcinoma and tumoral heterogeneity: a case report","volume":"12","author":"de Castria","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1387661","article-title":"Case Report: Second-line favourable effect of pembrolizumab plus chemotherapy in a patient with metastatic hepatoid adenocarcinoma of the stomach","volume":"16","author":"Tang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1496342","article-title":"Hepatoid adenocarcinoma of the stomach with ideal response to neoadjuvant chemo-immunotherapy: a case report","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1513604","article-title":"Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review","volume":"16","author":"Lu","year":"2025","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2023.1133335","article-title":"Pathologic complete response of hepatoid adenocarcinoma of the stomach after chemo-immunotherapy: A rare case report and literature review","volume":"10","author":"Zhou","year":"2023","journal-title":"Front Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"1) Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12336","article-title":"Genomic profiling and the impact of MUC19 mutation in hepatoid adenocarcinoma of the stomach","volume":"42","author":"Zhu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e2128217","DOI":"10.1001\/jamanetworkopen.2021.28217","article-title":"Assessment of clinicopathological characteristics and development of an individualized prognostic model for patients with hepatoid adenocarcinoma of the stomach","volume":"4","author":"Lin","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.633916","article-title":"Hepatoid adenocarcinoma of the stomach: current perspectives and new developments","volume":"11","author":"Xia","year":"2021","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001768","article-title":"Development of a staging system for hepatoid adenocarcinoma of the stomach based on multicenter data: a retrospective cohort study","volume":"111","author":"Huang","year":"2025","journal-title":"Int J Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181f0a873","article-title":"Analysis of clinicopathologic features and prognostic factors in hepatoid adenocarcinoma of the stomach","volume":"34","author":"Liu","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.1002\/cjp2.343","article-title":"Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases","volume":"10","author":"Yang","year":"2024","journal-title":"J Pathol Clin Res"},{"key":"B29","article-title":"Clinicopathological characteristics and prognosis of alpha-fetoprotein positive gastric cancer in Chinese patients","volume":"8","author":"Wang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"6710428","DOI":"10.1155\/2019\/6710428","article-title":"Hepatoid adenocarcinoma of stomach: emphasis on the clinical relationship with alpha-fetoprotein-positive gastric cancer","volume":"2019","author":"Chen","year":"2019","journal-title":"BioMed Res Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-019-00965-5","article-title":"Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features","volume":"22","author":"Wang","year":"2019","journal-title":"Gastric Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.5301\/jbm.5000167","article-title":"High level of serum AFP is an independent negative prognostic factor in gastric cancer","volume":"30","author":"Chen","year":"2015","journal-title":"Int J Biol Markers"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i2.266","article-title":"Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP","volume":"24","author":"Wang","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10120-024-01562-x","article-title":"Volume of hepatoid component and intratumor M2 macrophages predict prognosis in patients with hepatoid adenocarcinoma of the stomach","volume":"28","author":"Taniguchi","year":"2025","journal-title":"Gastric Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12876-025-03883-2","article-title":"Dynamic variations in peripheral blood indices and their association with efficacy and adverse reactions of pd- 1 inhibitor combined chemotherapy in patients with advanced gastric cancer","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001119","article-title":"Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study","volume":"110","author":"Li","year":"2024","journal-title":"Int J Surg"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13143-w","article-title":"Neoadjuvant therapy with immune checkpoint inhibitors in gastric cancer: A systematic review and meta-analysis","volume":"30","author":"Li","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2018.11.006","article-title":"Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST)","volume":"107","author":"Watson","year":"2019","journal-title":"Eur J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002003","article-title":"S-1 and oxaliplatin combined with nanoparticle albumin-bound paclitaxel adjuvant chemotherapy for advanced gastric adenocarcinoma","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-024-01471-z","article-title":"Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial","volume":"27","author":"Jiang","year":"2024","journal-title":"Gastric Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S276969","article-title":"Effect of immune checkpoint inhibitors plus chemotherapy on advanced gastric cancer patients with elevated serum AFP or hepatoid adenocarcinoma","volume":"12","author":"Li","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"10502","DOI":"10.1038\/s41598-022-13739-4","article-title":"Ellipsoid calculations versus manual tumor delineations for glioblastoma tumor volume evaluation","volume":"12","author":"Le F\u00e8vre","year":"2022","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01531-0","article-title":"Implications of quantitative tumor and nodal regression rates for nasopharyngeal carcinomas after 45 Gy of radiotherapy","volume":"50","author":"Fang","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.14740\/jmc4263","article-title":"Alpha-fetoprotein-producing hepatoid adenocarcinoma of the stomach","volume":"15","author":"Bathobakae","year":"2024","journal-title":"J Med Cases"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1648766\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T04:13:20Z","timestamp":1759378400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1648766\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":46,"alternative-id":["10.3389\/fonc.2025.1648766"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1648766","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"article-number":"1648766"}}